Skip to content
Hypromellose
Hypromellose is an unknown pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Searched
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
eye diseasesD005128
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
bion tearsOTC monograph final2023-05-18
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
dry eye syndromes—D015352H04.12
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01K: Surgical aids, ophthalmologic
— S01KA: Viscoelastic substances
— S01KA02: Hypromellose
HCPCS
No data
Clinical
Clinical Trials
145 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Dry eye syndromesD015352H04.12257172050
GlaucomaD005901EFO_0000516H4011—5411
Allergic conjunctivitisD003233EFO_0007141H10.44—1—9—10
Ocular hypertensionD009798EFO_1001069H40.0—1—6—7
PainD010146EFO_0003843R52———246
Meibomian gland dysfunctionD000080343H02.88———246
Open-angle glaucomaD005902EFO_0004190H40.1——1214
Intraocular pressureD007429———123
Keratoconjunctivitis siccaD007638EFO_1000906———112
Macular edemaD008269—111—2
Show 9 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type c niemann-pick diseaseD052556Orphanet_646E75.242421——5
Viral conjunctivitisD003236EFO_0008571B30—12—13
KeratitisD007634H16—22—13
Macular degenerationD008268EFO_0001365H35.30—11—12
Acanthamoeba keratitisD015823EFO_0007126—11——2
TrichiasisD058457HP_0001128——1—12
Eye diseasesD005128EFO_0003966H44——1—12
Wet macular degenerationD057135EFO_0004683—11——1
Healthy volunteers/patients———1——1
Exfoliation syndromeD017889EFO_0004235——1——1
Show 4 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Herpes zosterD006562EFO_0006510B02—1———1
Thyroid neoplasmsD013964EFO_0003841—1———1
Alzheimer diseaseD000544EFO_0000249F03—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CataractD002386EFO_0001059H26.91———23
Diabetic retinopathyD003930EFO_00037701————1
Brain neoplasmsD001932EFO_0003833C711————1
Sturge-weber syndromeD013341Orphanet_3205Q85.891————1
Port-wine stainD019339Q82.51————1
HyperemiaD006940EFO_0003822H34.821————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Sjogren's syndromeD012859EFO_0000699M35.0————22
StrabismusD013285HP_0000486H50.2————11
Adenoviridae infectionsD000257EFO_1001259B34.0————11
Corneal diseasesD003316H18.9————11
ConjunctivitisD003231H10————11
TrachomaD014141A71————11
MicrobiotaD064307————11
BlepharitisD001762EFO_0009536H01.0————11
Eye painD058447HP_0200026H57.1————11
MyopiaD009216H52.1————11
Show 1 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameHYPROMELLOSE
INNhypromellose
Description
Hypromellose (INN), short for hydroxypropyl methylcellulose (HPMC), is a semisynthetic, inert, viscoelastic polymer used in eye drops, as well as an excipient and controlled-delivery component in oral medicaments, found in a variety of commercial products.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID9004-65-3
RxCUI27334
ChEMBL IDCHEMBL2108956
ChEBI ID—
PubChem CID—
DrugBankDB11075
UNII ID3NXW29V3WO (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,154 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
3,144 adverse events reported
View more details